Patent assignee · US · COMPANY

ALDERBIO HOLDINGS LLC

103Patents

98Active

103Granted

57Portfolio score

Filing activity: May 21, 2008 → Aug 30, 2018 · 16 expiring within 5 years

Most-cited patents

Patent	Title	Area	Cited by	Status
US7935340B2	Antibodies to IL-6 and use thereof	Chemistry; Metallurgy	82	Active
US8323649B2	Antibodies to IL-6 and use thereof	Emerging Cross-Sectional Technologies	54	Active
US7906117B2	Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever	Chemistry; Metallurgy	53	Active
US8277804B2	Antagonists of IL-6 to prevent or treat thrombosis	Chemistry; Metallurgy	51	Active
US8062864B2	Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies	Chemistry; Metallurgy	50	Active
US8337847B2	Methods of treating anemia using anti-IL-6 antibodies	Emerging Cross-Sectional Technologies	48	Active
US8178101B2	Use of anti-IL-6 antibodies having specific binding properties to treat cachexia	Chemistry; Metallurgy	48	Active
US8252286B2	Antagonists of IL-6 to prevent or treat thrombosis	Chemistry; Metallurgy	48	Active
US8911734B2	Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75	Emerging Cross-Sectional Technologies	38	Active
US9255154B2	Anti-PCSK9 antibodies and use thereof	Physics	32	Active
US8404235B2	Antagonists of IL-6 to raise albumin and/or lower CRP	Physics	29	Active
US8420089B2	Antagonists of IL-6 to raise albumin and/or lower CRP	Chemistry; Metallurgy	28	Active
US8535671B2	Methods of reducing CRP and/or increasing serum albumin in patients in need using IL-6 antibodies of defined epitopic specificity	Physics	26	Active
US8728473B2	Methods of preventing or treating pain using anti-NGF antibodies	Emerging Cross-Sectional Technologies	26	Active
US8992920B2	Anti-IL-6 antibodies for the treatment of arthritis	Physics	25	Active
US9085615B2	Antibodies to IL-6 to inhibit or treat inflammation	Emerging Cross-Sectional Technologies	24	Active
US9452227B2	Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments	Emerging Cross-Sectional Technologies	22	Active
US9745373B2	Anti-CGRP compositions and use thereof	Chemistry; Metallurgy	18	Active
US9855332B2	Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels	Emerging Cross-Sectional Technologies	18	Active
US9708393B2	Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers	Emerging Cross-Sectional Technologies	18	Active
US9884912B2	Antibodies to IL-6 and use thereof	Chemistry; Metallurgy	15	Active
US9701747B2	Method of improving patient survivability and quality of life by anti-IL-6 antibody administration	Physics	14	Active
US10066009B2	Anti-CGRP compositions and use thereof	Chemistry; Metallurgy	14	Active
US9518082B2	Antibody purification and purity monitoring	Chemistry; Metallurgy	13	Active
US10189895B2	Anti-CGRP compositions and use thereof	Chemistry; Metallurgy	12	Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.